LMO2 expression is considered a prognostic biomarker not only in hematological malignancies, but also in solid tumors as pancreatic cancer and lung cancer (Aly et al., 2016; Cai et al., 2019; Nakata et al., 2009; Toffolatti et al., 2014). This evidence concerns the gene LMO2 and familial pancreatic carcinoma.